Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan

• Kanematsu Takanori

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Hanibuchi Masaki

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Tomimoto Hideki

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Sakiyakma Shoji

  Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Kenzaki Koichiro

  Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Kondo Kazuya

  Department of Oncological Medical Services, Institute of Health Biosciences, the University of Tokushima Gradate School

• Bando Hiroyasu

  Department of Respiratory Medicine, Tokushima Prefectural Central Hospital

• Haku Takashi

  Department of Respiratory Medicine, Tokushima Prefectural Central Hospital

• Yoneda Kazuo

  Department of Respiratory Medicine, Tokushima Prefectural Central Hospital

• Hirose Toshiyuki

  Department of Surgery, Tokushima Prefectural Central Hospital

• Toyoda Yuko

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Goto Hisatsugu

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Sakaguchi Satoshi

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Kinoshita Katsuhiro

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Azuma Momoyo

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Kakiuchi Soji

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Kishi Jun

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Azuma Masahiko

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Tada Hiroya

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Sumitomo Masayuki

  Department of Surgery, Tokushima Prefectural Central Hospital

• Nishioka Yasuhiko

  Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

• Yano Seiji

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School Division of Medical Oncology, Cancer Research Institute, Kanazawa University

• Sone Saburo

  Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School

抄録

Lung cancer is the leading cause of malignancy-related death worldwide. In the present study, we reviewed the epidemiologic and clinical features of lung cancer in Tokushima Prefecture, Japan. Between January 1999 and December 2009, 2,183 patients with lung cancer were enrolled in this study. One thousand five hundred ninety-one (73%) patients were male and 592 (27%) patients were female. Median age was 70 years, with a range of 15-93 years. Seventy-six percent of patients had smoking history. One thousand nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological type was adenocarcinoma (51%). Among all 2,183 patients, 702 (32%) belonged to elderly population. Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively. In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and 216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, thoracic radiotherapy, operation and best supportive care, respectively. The median time to progression (TTP) and the median survival time (MST) of patients treated with chemotherapy and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months, respectively. The median TTP and the MST of 33 elderly patients treated with chemotherapy were 3.3 months and 18.0 months, respectively, which were comparable with those of total population. These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection. J. Med. Invest. 57: 326-333, August, 2010

収録刊行物

• The Journal of Medical Investigation

  The Journal of Medical Investigation 57 (3,4), 326-333, 2010

  国立大学法人　徳島大学医学部

キーワード

• epidemiology
• lung cancer
• Tokushima Prefecture

詳細情報

• CRID: 1390282679220396160
• NII論文ID: 130004465225
• NII論文ID: 80021262352
• NII書誌ID: AA11166929
• DOI: 10.2152/jmi.57.326
• ISSN: 13496867
• ISSN: 13431420
• Web Site: http://repo.lib.tokushima-u.ac.jp/79184
• Web Site: http://www.jstage.jst.go.jp/article/jmi/57/3,4/57_3,4_326/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2011238219
• 本文言語コード: en
• データソース種別:
  • JaLC
  • IRDB
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可